ArticleResearch square2021
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Michael Diamond, Rita Chen, Xuping Xie, James Case, Xianwen Zhang, Laura VanBlargan, Yang Liu, Jianying Liu, John Errico, Emma Winkler and 21 more
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 88 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
31 authors at 5 institutions in 1 country.
Michael DiamondWashington University School of Medicine.
Rita ChenWashington University School of Medicine.
Xianwen ZhangUTMB.
Laura VanBlarganWashington University.
Yang LiuUniversity of Texas Medical Branch.
Jianying LiuUniversity of Texas Medical Branch.
John ErricoWashington University.
Emma WinklerWashington University School of Medicine.
Naveenchandra SuryadevaraVanderbilt University Medical Center.
Stephen TahanWashington University.
Jackson TurnerWashington University School of Medicine.
Mahima ThapaWashington University.
David WangWashington University in St. Louis.
Andrianus BoonWashington University School of Medicine.
Dora PintoHumabs BioMed SA, a subsidiary of Vir Biotechnology, Inc.
Rachel PrestiWashington University School of Medicine.
Jane O'HalloranWashington University School of Medicine.
Alfred KimWashington University.
Parakkal DeepakWashington University.
Lindsay DroitWashington University School of Medicine.
Pavlo GilchukVanderbilt University Medical Center.
The University of Texas Medical Branch at Galveston · USVanderbilt University Medical Center · USTexas Medical Board · USVIR Biotechnology (United States) · USWashington University in St. Louis · US
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MUTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0MProject 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MCOVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7MB-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2MEmerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0MWashington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MProgramming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MDiscovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsR43AI145617 · NIAID · PLEX PHARMACEUTICALS, INC. · PI REMACLE, ALBERT, THOTA, SAMBAIAH · 2020 to 2021
$600kNCATS NIH HHS UL1 TR001439NCI NIH HHS T32 CA009547NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00062NIAID NIH HHS 75N93019C00074NIAID NIH HHS F30 AI152327NIAID NIH HHS HHSN272201400006CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI157155NIAID NIH HHS R43 AI145617NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI151810NIAID NIH HHS U19 AI142759NIAMS NIH HHS P30 AR073752
6 · The paper itselfAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths. The rapid deployment of antibody-based countermeasures has provided hope for curtailing disease and ending the pandemic
Identifiers
PMID33594356
PMCPMC7885928
OpenAlexW3126944781
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390